Heading into January 2026, consumer search behavior shows rising interest in non-prescription approaches to metabolic wellness, particularly around GLP-1-related terminology as prescription medications remain highly discussed and regulated
5 Market outlook Eli Lillys oral non-peptide GLP-1RA orforglipron is advancing through the ACHIEVE Phase III program, with Lilly signaling regulatory submissions for obesity in 2025 and type 2 diabetes in 2026, following positive results from both Phase 2 obesity (GZGI) and Phase 3 T2DM (ACHIEVE-1) trials
Why Are Researchers Interested in Melanotan I
We prioritize safety, monitoring, and long-term outcomesnot quick fixes
Use your routine consistently for at least 34 weeks before judging results
Watch video Contact Digital event video 26 August 2020 Pharmacy Practice Research priorities during the COVID-19 pandemic Moderators: Charlotte Verner Rossing and Dalia Dawoud